These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28124511)

  • 101. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
    Torres HA; Economides MP; Angelidakis G; Hosry J; Kyvernitakis A; Mahale P; Jiang Y; Miller E; Blechacz B; Naing A; Samaniego F; Kaseb A; Raad II; Granwehr BP
    Am J Gastroenterol; 2019 Feb; 114(2):250-257. PubMed ID: 30410039
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S; Guerra I; Cammà C; Craxì A; Carosi G
    J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.
    Rezaee-Zavareh MS; Hesamizadeh K; Behnava B; Alavian SM; Gholami-Fesharaki M; Sharafi H
    Ann Hepatol; 2017; 16(2):188-197. PubMed ID: 28233739
    [No Abstract]   [Full Text] [Related]  

  • 104. Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
    Chuang WL; Hu TH; Buggisch P; Moreno C; Su WW; Biancone L; Camargo M; Hyland R; Lu S; Kirby BJ; Dvory-Sobol H; Osinusi A; Gaggar A; Peng CY; Liu CH; Sise ME; Mangia A
    Am J Gastroenterol; 2021 Sep; 116(9):1924-1928. PubMed ID: 34465694
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
    Ohta Y; Kanda T; Katsuno T; Yasui S; Haga Y; Sasaki R; Nakamura M; Wu S; Nakamoto S; Arai M; Yokosuka O
    BMC Gastroenterol; 2016 Jul; 16(1):66. PubMed ID: 27401874
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
    Faraj OA; AlBayati SM
    J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S105-S109. PubMed ID: 35130230
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
    Smith SK; Rosenthal P
    J Pediatr Gastroenterol Nutr; 2016 Nov; 63(5):516-517. PubMed ID: 27243422
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
    J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
    Sterling RK; Cherian R; Lewis S; Genther K; Driscoll C; Martin K; Goode MB; Matherly S; Siddiqui MS; Luketic VA; Stravitz RT; Puri P; Lee H; Smith P; Patel V; Sanyal AJ
    J Correct Health Care; 2018 Apr; 24(2):127-136. PubMed ID: 29566611
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
    Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
    Hepatology; 2016 Dec; 64(6):1893-1899. PubMed ID: 27533287
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
    J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
    Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
    J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
    Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
    [No Abstract]   [Full Text] [Related]  

  • 116. Effectiveness of the Treatment of Chronic Hepatitis C Virus Infection Genotype 2 by the Combination Sofosbuvir/Ledipasvir in a Black African Kidney Transplant.
    Lawson-Ananissoh LM; Anzouan-Kacou YHK; Tsevi YM; Ackoundou-N'Guessan KC; Attia KA
    West Afr J Med; 2019; 36(3):280-282. PubMed ID: 31622492
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Weng Q; Li X; Ren H; Xie J; Pan X; Xu J; Chen N
    Oncotarget; 2017 Mar; 8(13):22299-22303. PubMed ID: 28223549
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
    German P; Mathias A; Brainard D; Kearney BP
    Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.
    Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV
    Hepatology; 2016 Dec; 64(6):1911-1921. PubMed ID: 27639183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.